Entering text into the input field will update the search result below

Ginkgo Bioworks meets 2022 revenue outlook

Stock Market Capital Gains Increasing From A Bull Market

Darren415

The cell programming platform company, Ginkgo Bioworks (NYSE:DNA), pre-announced its 2022 financials on Wednesday, indicating $460M – $480M in revenue and 55-60 new cell programs based on preliminary unaudited estimates.

The projections meet the company's previously disclosed guidance

Recommended For You

About DNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DNA--
Ginkgo Bioworks Holdings, Inc.